CAS: 145-12-0; (8R,9S,10R,13S,14S,17S)-4,17-Dihydroxy-10,13,17-Trimethyl-2,6,7,8,9,11,12,14,15,16-Decahydro-1H-Cyclopenta[a]Phenanthren-3-One

该化合物是来自睾丸酮的合成新陈代谢类类固醇,其特点是其强大的代谢性能,可促进肌肉生长,提高体性性能;化学上,它是17个丙烯酸酯的衍生物,可使其抗抗艾氏肝脏的代谢性破裂,从而增加其生物利用率;有机甲酮一般是口服的,以其增加体内氮保留和蛋白合成的能力为名;这种化合物经常用于医疗环境,治疗肌肉消瘦和某些类型的贫血等条件;然而,它也与一系列潜在的副作用有关,包括肝脏毒性,荷尔蒙不平衡和心血管问题;由于其性能增强效应,在竞争运动中禁用了氧丙酮,在许多国家被归类为受管制的物质;与任何代谢类类类的类固醇一样,应谨慎对待其使用,并在医疗监督下减轻健康风险.

结构式图片

物理性质

MSDS等安全信息

欧盟法规

ECHA物质ECHA物质C&L通报REACH预注册

上下游产品

CAS号2320-90-3 17α-Methyl-4,6-... | CAS号58-18-4 甲基睾酮 | CAS号5785-58-0 4-Chloro-17α-me...

合成工艺路线路线简述

    📜4-氯甲睾酮置于palladium On Activated Charcoal Potassium Tert-Butylate,氢气体系中,用 乙醇,叔丁醇 用作溶剂,化学反应生成羟甲睾酮
    参考文献:Camerino,B. Et Al.,Gazzetta Chimica Italiana,1962,Vol. 92,P. 693-708
    标题:Camerino,B. Et Al.,Gazzetta Chimica Italiana,1962,Vol. 92,P. 693-708

    海关参考信息

    专利信息


    专利号:US-2014274978-A1
    优先权日:2013-03-15
    标题 :Phytosterol spirostane and spirostene derivatives having a wide variety of utilities in humans and other animals
    发明人：FASCIOLA ANDRE ARMEL
    权利人:FASCIOLA ANDRE ARMEL
    摘要:The present invention utilizes phytosterol, phytoecdysteroid, sapogenin, triterpene, terpene, spirostane, spirostene and androstene derivative compounds to provide a wide variety of utilities to humans and other animals. The compounds and methods provide numerous and wide-ranging benefits including biochemical and constructive metabolic benefits including increases in protein synthesis and synthesis efficiency, ergogenic, adaptogenic, cosmetic and medicinal skin agents and veterinary utilities. The compounds provide agents that increase physical endurance and work output, act as a general tonic for increasing health and vigor, increase sleep time and sleep efficiency and act as rejuvenating agents to reverse the effects of fatigue and stress. Novel utilities for pet, farm, zoo and companion animals are also provided.

    专利号:US-2025281509-A1
    优先权日:2021-04-26
    标 题 :Sequential hormone therapy to improve survival and enhance response to immune therapy in men with prostate cancer
    发明人：DENMEADE SAMUEL R; ISAACS JOHN T; ANTONARAKIS EMMANUEL S; KACHHAP SUSHANT; MARKOWSKI MARK CHRISTOPHER
    权利人:UNIV JOHNS HOPKINS
    摘要:Disclosed are methods for treating men with castrate resistant prostate cancer with a sufficient dose of testosterone to achieve supraphysiologic serum levels of testosterone in sequence with androgen ablative treatment or androgen synthesis inhibitors for one or more cycles until evidence of radiographic progression, at which point the subject will receive immune checkpoint blockade therapy.

    其他信息查阅

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    实用工具

    ⚠️全国化工行业净网倡议书
    📋制造商识别码
    📖 海关编码查询
    📝MSDS生成器

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献


    摘要:21 CFR Sections 1308.11-1308.15
    摘要:S109 | PARCEDC | List of 7074 potential endocrine disrupting compounds (EDCs) by PARC T4.2 | DOI:10.5281/zenodo.10944198
    摘要:S72 | NTUPHTW | Pharmaceutically Active Substances from National Taiwan University | DOI:10.5281/zenodo.3955664
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知